Abstract
Dual binding site acetylcholinesterase inhibitors have recently emerged as a new class of anti-Alzheimer agents with potential to positively modify the course of the disease. These compounds exhibit a multifunctional pharmacological profile arising from interaction with several biological targets involved upstream and downstream in the neurodegenerative cascade of Alzheimers disease (AD). The primary target of these compounds is the enzyme acetylcholinesterase (AChE). Interaction of dual binding site AChE inhibitors with AChE results in a potent inhibitory activity of AChE and AChE-induced β-amyloid peptide (Aβ) aggregation. Some dual binding site AChE inhibitors take on added value a significant ability to additionally inhibit the enzymes butyrylcholinesterase and BACE-1, involved in the co-regulation of the hydrolysis of the neurotransmitter acetylcholine and in Aβ formation, respectively. The structural determinants which mediate the interaction of dual binding site AChE inhibitors with these three important enzymes for AD treatment are herein reviewed.
Keywords: Acetylcholinesterase, butyrylcholinesterase, BACE-1, drug-target interactions, structure-based drug design, Anti-Alzheimer agents, Alzheimer's disease, AChE inhibitors, b-amyloid peptide, Dementia, Endoproteinases, Ab vaccine, Ramiprosate, AN1792, Bapineuzumab, CTS-21166, LY450139, MK 0752, E2012, Tacrine, Donepezil, Rivastigmine, Galantamine, Protofibrils, Amylospheroids, Torpedo californica, Thioflavin T fluorescence, Anti-TZ2PA6, Physostigmine analogue, BChE inhibitors, Memoquin
Current Pharmaceutical Design
Title: Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents
Volume: 16 Issue: 25
Author(s): Carles Galdeano, Elisabet Viayna, Pau Arroyo, Axel Bidon-Chanal, J. Ramon Blas, Diego Munoz-Torrero and F. Javier Luque
Affiliation:
Keywords: Acetylcholinesterase, butyrylcholinesterase, BACE-1, drug-target interactions, structure-based drug design, Anti-Alzheimer agents, Alzheimer's disease, AChE inhibitors, b-amyloid peptide, Dementia, Endoproteinases, Ab vaccine, Ramiprosate, AN1792, Bapineuzumab, CTS-21166, LY450139, MK 0752, E2012, Tacrine, Donepezil, Rivastigmine, Galantamine, Protofibrils, Amylospheroids, Torpedo californica, Thioflavin T fluorescence, Anti-TZ2PA6, Physostigmine analogue, BChE inhibitors, Memoquin
Abstract: Dual binding site acetylcholinesterase inhibitors have recently emerged as a new class of anti-Alzheimer agents with potential to positively modify the course of the disease. These compounds exhibit a multifunctional pharmacological profile arising from interaction with several biological targets involved upstream and downstream in the neurodegenerative cascade of Alzheimers disease (AD). The primary target of these compounds is the enzyme acetylcholinesterase (AChE). Interaction of dual binding site AChE inhibitors with AChE results in a potent inhibitory activity of AChE and AChE-induced β-amyloid peptide (Aβ) aggregation. Some dual binding site AChE inhibitors take on added value a significant ability to additionally inhibit the enzymes butyrylcholinesterase and BACE-1, involved in the co-regulation of the hydrolysis of the neurotransmitter acetylcholine and in Aβ formation, respectively. The structural determinants which mediate the interaction of dual binding site AChE inhibitors with these three important enzymes for AD treatment are herein reviewed.
Export Options
About this article
Cite this article as:
Galdeano Carles, Viayna Elisabet, Arroyo Pau, Bidon-Chanal Axel, Ramon Blas J., Munoz-Torrero Diego and Javier Luque F., Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents, Current Pharmaceutical Design 2010; 16 (25) . https://dx.doi.org/10.2174/138161210793176536
DOI https://dx.doi.org/10.2174/138161210793176536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Hypertension and Counter-Hypertension Mechanisms in Giraffes
Cardiovascular & Hematological Disorders-Drug Targets Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry Smoking and Cognition
Current Drug Abuse Reviews Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design What We Learnt from Randomized Clinical Trials and Cohort Studies of Antioxidant Vitamin? : Focus on Vitamin E and Cardiovascular Disease
Current Pharmaceutical Biotechnology Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Early, Intensive and Long-term Statin Therapy in Acute Coronary Syndrome: Focus on Anti-inflammatory Mechanisms
Vascular Disease Prevention (Discontinued) Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Altered Calcium Handling in Reperfusion Injury
Medicinal Chemistry Material-Based Engineering Strategies for Cardiac Regeneration
Current Pharmaceutical Design The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design